Background
Sheri Hartman visited the emergency department at Portneuf Medical Center (PMC) in Pocatello twice in November 2019 for severe back pain. On her second visit, Physician Assistant Amber Schroeder—supervised by Dr. Willis Parmley—applied a 50-microgram transdermal fentanyl (Duragesic) patch and discharged Mrs. Hartman with instructions to obtain additional patches from her primary care physician. Two days later, orthopedic surgeon Dr. Stephen Hansen examined Mrs. Hartman, noted she was still in significant pain despite the patch, and prescribed eight additional fentanyl patches to manage pain until surgery. Mrs. Hartman died on November 25, 2019; her death certificate listed respiratory depression, acute fentanyl intoxication, and fentanyl overdose as causes of death.
Her husband and adult children filed suit in 2021 alleging medical malpractice and informed-consent violations against the emergency providers (PA Schroeder, Dr. Parmley, and their group, RMPG), Dr. Hansen and his practice, and PMC. A central discovery dispute arose when the Hartmans retained out-of-state liability experts who had consulted with unnamed local Idaho physicians to familiarize themselves with Pocatello’s standard of care. Defendants requested the identities of those local consultants; the Hartmans refused and sought a protective order, arguing the local consultants feared professional retaliation. The Hartmans later contended their experts primarily relied on Dr. Parmley’s own deposition testimony—in which he stated the local and national emergency-medicine standards of care were identical—and therefore had no obligation to disclose the local consultants at all.
The district court denied the protective order, found the Hartmans’ non-disclosure intentional and unjustified, and struck all three liability experts as a discovery sanction. The court then granted summary judgment to all defendants: to the emergency providers and PMC on causation (holding the Hartmans failed to show the single patch dispensed at PMC contributed to Mrs. Hartman’s death days later), and to all remaining defendants on the malpractice and informed-consent claims for lack of admissible expert testimony on breach of the standard of care. The Hartmans appealed.
The Court’s Holding
The Idaho Supreme Court affirmed the discovery sanctions, reversed the causation summary judgment as to PMC, and remanded for further proceedings against PMC only. On the expert-disclosure issue, the court reaffirmed Quigley v. Kemp, 162 Idaho 408 (2017), and held that Idaho Rule of Civil Procedure 26(b)(4)(A)(i) requires disclosure of non-testifying local standard-of-care experts whenever a testifying expert relies on them to any degree—not only when they serve as the primary basis for the opinion. The court rejected the Hartmans’ argument that their experts’ secondary reliance on local consultants excused disclosure, finding no such distinction in the rule’s plain language requiring disclosure of “all” bases, reasons, and data considered. The intentional, months-long withholding without substantial justification supported the district court’s decision to strike the experts and affirmed that decision as within discretion.
On proximate causation, the court announced a clarifying rule: in a medical malpractice case, a plaintiff need only show that a reasonable provider in the defendant’s position would have foreseen the general risk of harm from the allegedly negligent treatment—not the precise pharmacokinetic mechanism through which injury occurred. Applying that standard, the court found the district court erred in granting summary judgment against PMC solely because the Hartmans’ causation experts did not specifically rebut defense evidence that no fentanyl from the original ER patch would have remained active at the time of death. The general risk of fatal opioid overdose from fentanyl patch therapy was the relevant foreseeability question, and that issue remained contested. Because the Hartmans’ claims against all defendants other than PMC were properly dismissed through the sanctions ruling (leaving no live liability expert for those parties), only the claim against PMC—including the separately preserved informed-consent claim—survives on remand.
Key Takeaways
- Idaho Rule 26(b)(4)(A)(i) requires disclosure of every non-testifying local standard-of-care consultant a testifying expert relied on, even secondarily; there is no primary-versus-secondary exception.
- A plaintiff’s intentional refusal to disclose local consultants—even while asserting a good-faith protective-order theory—may support the severe sanction of striking all liability experts, effectively ending most claims.
- In Idaho medical malpractice cases, proximate causation foreseeability turns on whether the defendant could have anticipated the general type of harm (e.g., opioid overdose), not the specific biological mechanism that produced it.
- A defendant’s own deposition testimony that local and national standards of care are identical does not relieve the plaintiff of the obligation to separately disclose local consulting experts who assisted the plaintiff’s testifying witnesses.
Why It Matters
This decision tightens disclosure obligations for plaintiffs in Idaho medical malpractice cases and removes what had been a potential escape hatch: the argument that expert reliance on a local consultant was merely incidental. Under the court’s reading of Quigley and Rule 26, any reliance on a local standard-of-care consultant triggers mandatory disclosure, and strategic delay or refusal risks case-dispositive sanctions. Defense counsel can now point to this opinion to compel full identification of local shadow experts at the outset of litigation.
The court’s proximate-causation ruling is equally significant for plaintiffs. By anchoring foreseeability to the general risk of harm rather than the specific mechanism of injury, the decision aligns Idaho law with the majority approach and prevents defendants from defeating causation merely by showing the plaintiff cannot trace every physiological step between treatment and death. Plaintiffs in complex pharmaceutical or multi-provider cases will now have a clearer path to surviving summary judgment on causation, provided their expert evidence addresses the foreseeable category of harm.